Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DWP16001 + DWC202010
- Development stage
- Unknown
- Lead developer
- Daewoong Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**DWP16001 + DWC202010** is an investigational combination drug therapy composed of DWP16001, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, and DWC202010, a code name for phentermine. - **Mechanism of Action:** - DWP16001 (Enavogliflozin) inhibits SGLT2 in the kidney, reducing glucose reabsorption and promoting glucosuria, thereby lowering blood glucose and causing modest weight loss[2][5]. - DWC202010 (phentermine) is a sympathomimetic amine that acts as an appetite suppressant, primarily stimulating noradrenergic pathways within the central nervous system[2]. - **Indications:** The combination is being evaluated for **obesity** and **type 2 diabetes mellitus**, with supporting evidence for potential use in heart failure[4]. - **Development:** Clinical studies have assessed pharmacokinetics, pharmacodynamics, and safety in healthy adults. The combination demonstrates potential for additive weight loss without significant drug-drug interactions or adverse metabolic effects[1][2][4].
- Brand names
- Envlo
- Other names
- DWP16001DWP-16001DWP 16001DWC202010DWC-202010DWC 202010Enavogliflozinphentermine
02
Targets
SGLT2 (Sodium-glucose cotransporter protein subunit 2)
Beyond the preview
Go deeper on DWP16001 + DWC202010.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DWP16001 + DWC202010.